DermTech, Inc. (NASDAQ:DMTK – Get Rating) COO Claudia Ibarra sold 2,449 shares of the stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $5.65, for a total value of $13,836.85. Following the completion of the transaction, the chief operating officer now directly owns 161,105 shares in the company, valued at $910,243.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Claudia Ibarra also recently made the following trade(s):

• On Tuesday, September 6th, Claudia Ibarra sold 133 shares of DermTech stock. The shares were sold at an average price of $5.43, for a total value of $722.19.
• On Monday, June 13th, Claudia Ibarra sold 345 shares of DermTech stock. The shares were sold at an average price of $4.81, for a total value of $1,659.45.

DermTech Trading Down 1.5 %

Shares of DMTK stock opened at $5.97 on Friday. The company has a market capitalization of $179.34 million, a P/E ratio of -1.68 and a beta of 1.49. The business's 50 day moving average is $6.57 and its two-hundred day moving average is $8.59. DermTech, Inc. has a 12-month low of $4.18 and a 12-month high of $36.80.

Analysts Set New Price Targets

Hedge Funds Weigh In On DermTech

Hedge funds have recently bought and sold shares of the business. Wolverine Asset Management LLC purchased a new position in DermTech during the fourth quarter worth approximately $43,000. Amalgamated Bank purchased a new position in shares of DermTech in the first quarter valued at approximately $58,000. Financial Management Professionals Inc. purchased a new position in shares of DermTech in the second quarter valued at approximately $26,000. Ensign Peak Advisors Inc purchased a new position in shares of DermTech in the fourth quarter valued at approximately $82,000. Finally, Integrated Advisors Network LLC purchased a new position in shares of DermTech in the first quarter valued at approximately $147,000. Hedge funds and other institutional investors own 58.74% of the company's stock.

About DermTech

(Get Rating)

DermTech, Inc, a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.

Featured Articles

• Get a free copy of the StockNews.com research report on DermTech (DMTK)
• MarketBeat: Week in Review 9/5 – 9/9
• Prepare For A Record-Setting Quarter For Cyber Security Stocks
• The Auto Market Is Slowly Recovering, These Stocks May Outperform
• Is DocuSign On The Verge Of A Major Reversal?
• Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy

Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.